|Bid||0.11 x 0|
|Ask||0.11 x 0|
|Day's Range||0.10 - 0.11|
|52 Week Range||0.08 - 0.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In this article, I’m going to take a look at GeneNews Limited’s (TSX:GEN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
If you are a shareholder in GeneNews Limited’s (TSX:GEN), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...
When GeneNews Limited (TSX:GEN) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peersRead More...
GeneNews Limited (TSX:GEN), a CADCA$12.04M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoingRead More...
On a per-share basis, the Markham, Ontario-based company said it had a loss of 1 cent. The genetic testing company posted revenue of $54,000 in the period. The company's shares closed at 9 cents. A year ...
The Markham, Ontario-based company said it had a loss of 1 cent per share. The genetic testing company posted revenue of $114,000 in the period. The company's shares closed at 13 cents. A year ago, they ...